Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study
出版年份 2020 全文链接
标题
Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study
作者
关键词
-
出版物
Frontiers in Immunology
Volume 11, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-07-17
DOI
10.3389/fimmu.2020.01382
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases
- (2019) Gecilmara Salviato Pileggi et al. Advances in Rheumatology
- Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis
- (2017) Anthony Lopez et al. JOURNAL OF AUTOIMMUNITY
- Safety of live vaccinations on immunosuppressive therapy in patients with immune-mediated inflammatory diseases, solid organ transplantation or after bone-marrow transplantation – A systematic review of randomized trials, observational studies and case reports
- (2017) Evelina Croce et al. VACCINE
- Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day
- (2017) Natalie D. Collins et al. Current Infectious Disease Reports
- 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome
- (2016) Caroline H Shiboski et al. ANNALS OF THE RHEUMATIC DISEASES
- Questions regarding the safety and duration of immunity following live yellow fever vaccination
- (2016) Ian J. Amanna et al. Expert Review of Vaccines
- 17D yellow fever vaccine elicits comparable long-term immune responses in healthy individuals and immune-compromised patients
- (2016) R.W. Wieten et al. JOURNAL OF INFECTION
- Comparison of the PRNT and an immune fluorescence assay in yellow fever vaccinees receiving immunosuppressive medication
- (2016) Rosanne W. Wieten et al. VACCINE
- A Single 17D Yellow Fever Vaccination Provides Lifelong Immunity; Characterization of Yellow-Fever-Specific Neutralizing Antibody and T-Cell Responses after Vaccination
- (2016) Rosanne W. Wieten et al. PLoS One
- Yellow Fever Vaccination of a Primary Vaccinee during Adalimumab Therapy
- (2015) Esther R. Nash et al. JOURNAL OF TRAVEL MEDICINE
- Vaccines and vaccination against yellow fever: WHO Position Paper, June 2013—Recommendations
- (2015) WHO VACCINE
- Seroconversion in Patients With Rheumatic Diseases Treated With Immunomodulators or Immunosuppressants, Who Were Inadvertently Revaccinated Against Yellow Fever
- (2015) Ana C. V. Oliveira et al. Arthritis & Rheumatology
- Defining Risk Groups to Yellow Fever Vaccine-Associated Viscerotropic Disease in the Absence of Denominator Data
- (2014) Stephen J. Seligman et al. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)
- (2014) Raphaèle Seror et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD)
- (2014) Stephen J. Seligman VACCINE
- Adaptação transcultural do “EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI)” para a língua portuguesa
- (2014) Érica Vieira Serrano et al. Revista Brasileira De Reumatologia
- Efficacy and Duration of Immunity after Yellow Fever Vaccination: Systematic Review on the Need for a Booster Every 10 Years
- (2013) Eduardo Gotuzzo et al. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
- 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative
- (2013) Frank van den Hoogen et al. ARTHRITIS AND RHEUMATISM
- Immunogenicity of Seven New Recombinant Yellow Fever Viruses 17D Expressing Fragments of SIVmac239 Gag, Nef, and Vif in Indian Rhesus Macaques
- (2013) Mauricio A. Martins et al. PLoS One
- Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases
- (2013) Despoina Papadopoulou et al. RHEUMATOLOGY INTERNATIONAL
- Safety and Immunogenicity of Yellow Fever 17D Vaccine in Adults Receiving Systemic Corticosteroid Therapy: An Observational Cohort Study
- (2013) Solen Kernéis et al. ARTHRITIS CARE & RESEARCH
- Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus
- (2012) Michelle Petri et al. ARTHRITIS AND RHEUMATISM
- Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies
- (2012) Marisol Simões et al. BIOLOGICALS
- Review of the risks and benefits of yellow fever vaccination including some new analyses
- (2012) Thomas P Monath Expert Review of Vaccines
- Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50: sensitivity to response at 6 and 12 months
- (2012) Z. Touma et al. RHEUMATOLOGY
- The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
- (2010) M. Rudwaleit et al. ANNALS OF THE RHEUMATIC DISEASES
- 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
- (2010) Daniel Aletaha et al. ARTHRITIS AND RHEUMATISM
- Yellow fever vaccine—how does it work and why do rare cases of serious adverse events take place?
- (2009) Alan DT Barrett et al. CURRENT OPINION IN IMMUNOLOGY
- Vacinação contra febre amarela em pacientes com diagnósticos de doenças reumáticas, em uso de imunossupressores
- (2009) Licia Maria Henrique da Mota et al. Revista da Sociedade Brasileira de Medicina Tropical
- ASAS-Klassifikationskriterien für axiale Spondyloarthritis
- (2009) M. Rudwaleit et al. ZEITSCHRIFT FUR RHEUMATOLOGIE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now